In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3534-3537

  Hornsey, M ^a   Wareham, D W ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; GENTAMICIN; GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CATERPILLAR; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GALLERIA MELLONELLA; IMMUNOMODULATION; LETHAL DOSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GLYCOPEPTIDES; LEPIDOPTERA; MICROBIAL SENSITIVITY TESTS;

EID: 79959214029     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00230-11     Document Type: Article

References (23)

1. Andrews, J. M., and BSAC Working Party on Susceptibility Testing. 2009. BSAC standardized disc susceptibility testing method (version 8). J. Antimicrob. Chemother. 64:454-489.
2. Brown, S. E., A. Howard, A. B. Kasprzak, K. H. Gordon, and P. D. East. 2009. A peptidomics study reveals the impressive antimicrobial peptide arsenal of the wax moth Galleria mellonella. Insect Biochem. Mol. Biol. 39:792-800.
3. Champion, O. L., et al. 2009. Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. Microbiology 155:1516-1522.
4. Coelho, J. M., et al. 2006. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J. Clin. Microbiol. 44:3623-3627.
5. Fishbain, J., and A. Y. Peleg. 2010. Treatment of Acinetobacter infections. Clin. Infect. Dis. 51:79-84.
6. Gordon, N. C., and D. W. Wareham. 2010. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int. J. Antimicrob. Agents 35:219-226.
7. Gordon, N. C., K. Png, and D. W. Wareham. 2010. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:5316-5322.
8. Hawley, J. S., C. K. Murray, and J. H. Jorgensen. 2008. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 52:351-352.
9. Hornsey, M., et al. 2010. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J. Antimicrob. Chemother. 65:1589-1593.
10. Hornsey, M., et al. 12 May 2011, posting date. Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J. Antimicrob. Chemother., doi:10.1093/jac/dkr168.
11. Jander, G., L. G. Rahme, and F. M. Ausubel. 2000. Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and insects. J. Bacteriol. 182:3843-3845.
12. Kavanagh, K., and E. P. Reeves. 2004. Exploiting the potential of insects for in vivo pathogenicity testing of microbial pathogens. FEMS Microbiol. Rev. 28:101-112.
13. Korman, T. M., J. D. Turnidge, and M. L. Grayson. 1997. Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J. Antimicrob. Chemother. 39:371-381.
14. Levin, A. S., et al. 1999. Intravenous colistin as therapy for nosocomial infections caused by multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28:1008-1011.
15. Owen, R. J., J. Li, R. L. Nation, and D. Spelman. 2007. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother. 59:473-477.
16. Park, Y. K., et al. 2009. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn. Microbiol. Infect. Dis. 64:43-51.
17. Peleg, A. Y., H. Seifert, and D. L. Paterson. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
18. Peleg, A. Y., et al. 2009. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob. Agents Chemother. 53:2605-2609.
19. Seed, K. D., and J. J. Dennis. 2008. Development of Galleria mellonella as an alternative infection model for the Burkholderia cepacia complex. Infect. Immun. 76:1267-1275.
20. Sivagnanam, S., and D. Deleu. 2003. Red man syndrome. Crit. Care 7:119-120. (Pubitemid 36432668)
21. Vaara, M. 1992. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56:395-411.
22. Wareham, D. W., et al. 2008. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 27:607-612.
23. Wareham, D. W., N. C. Gordon, and M. A. Hornsey. 8 March 2011. In vitro activity of teicoplanin combined with colistin versus multi-drug resistant strains of Acinetobacter baumannii (MDRAB). J. Antimicrob. Chemother. doi:10.1093/jac/dkr069.